AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17364528 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intensity of rehabilitation
Number of subjects: 0
Study 17364528 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct patient involvement in neurorehabilitation goal setting
Number of subjects: 0
Study 15900358 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage
Number of subjects: 150
Study 15900358 — intervention group
Group type: COMPARATOR
Intervention: Drainage
Number of subjects: 150
Study 11885848 — intervention group
Group type: EXPERIMENTAL
Intervention: Minidose warfarin (1 mg daily)
Number of subjects: 0
Study 11885848 — intervention group
Group type: COMPARATOR
Intervention: Control (no warfarin)
Number of subjects: 0
Study 10206930 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol and repeated performance (A-R)
Number of subjects: 80
Study 10206930 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol and double performance (A-D)
Number of subjects: 80
Study 10206930 — intervention group
Group type: COMPARATOR
Intervention: Placebo and repeated performance (P-R)
Number of subjects: 80
Study 10206930 — intervention group
Group type: COMPARATOR
Intervention: Placebo and double performance (P-D)
Number of subjects: 80
Study 7572323 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplement (500 mg/day)
Number of subjects: 229
Study 7572323 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mean calcium intake = 376 mg/day)
Number of subjects: 229
Study 2190885 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (7 g/sqm) + GM-CSF (5.5 micrograms/kg per day for 7-14 days)
Number of subjects: 17
Study 2190885 — intervention group
Group type: COMPARATOR
Intervention: High-dose cyclophosphamide (7 g/sqm)
Number of subjects: 17
Study 7002739 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone enemas (Cortenemas)
Number of subjects: 30
Study 7002739 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone foam (Colifoam)
Number of subjects: 30
Study 31199849 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component breastfeeding support intervention (antenatal education, professional and peer support, delivered in hospital and home settings for six months)
Number of subjects: 362
Study 31199849 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component breastfeeding support intervention
Number of subjects: 362
Study 31199849 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component breastfeeding support intervention (compliance with all three components)
Number of subjects: 362
Study 31199849 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 362
Study 28107560 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-stable collagen matrix (VCMX)
Number of subjects: 20
Study 28107560 — intervention group
Group type: COMPARATOR
Intervention: Autogenous subepithelial connective tissue graft (SCTG)
Number of subjects: 20
Study 25878180 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mild Alzheimer's disease (AD) dementia
Number of subjects: 87
Study 25878180 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mild cognitive impairment
Number of subjects: 87
Study 25878180 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 87
Study 23746490 — intervention group
Group type: EXPERIMENTAL
Intervention: VR conversation
Number of subjects: 26
Study 23746490 — intervention group
Group type: COMPARATOR
Intervention: In vivo conversation
Number of subjects: 26
Study 20538293 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser therapy (n = 25), using Ga-As laser device with wavelength of 904 nm, power of 5 mW, and spot size of 0.2 cm², applied three times a week for 12 weeks, total energy of 300 mjoules over seven points (1.5 joules/cm²).
Number of subjects: 50
Study 20538293 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy (n = 25), where the laser was disabled but appeared functional.
Number of subjects: 50
Study 19070889 — intervention group
Group type: COMPARATOR
Intervention: Standard surgery (hysterectomy and BSO, peritoneal washings, and palpation of para-aortic nodes)
Number of subjects: 1408
Study 19070889 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard surgery plus lymphadenectomy
Number of subjects: 1408
Study 16871726 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention with home care and access to care team via call center
Number of subjects: 157
Study 16871726 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 157
Study 16871726 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 157
Study 11895893 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg
Number of subjects: 456
Study 11895893 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg
Number of subjects: 456
Study 10367757 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic therapy
Number of subjects: 54
Study 10367757 — intervention group
Group type: COMPARATOR
Intervention: Non-PMS group (control)
Number of subjects: 54
Study 7777014 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin therapy
Number of subjects: 177216
Study 2184634 — intervention group
Group type: EXPERIMENTAL
Intervention: Total stripping of the long saphenous vein (Group A)
Number of subjects: 163
Study 2184634 — intervention group
Group type: COMPARATOR
Intervention: Partial stripping of the long saphenous vein (Group B)
Number of subjects: 163
Study 7403330 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of dextrose and water with different magnesium, calcium, and potassium solutions
Number of subjects: 9
Study 7403330 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential regulation of oral water intake to induce 1, 2, 4, and 8 liters of urine volume/day on a low sodium diet (40 mEq)
Number of subjects: 9
Study 7403330 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential regulation of oral water intake to induce 1, 2, 4, and 8 liters of urine volume/day on a high sodium diet (200 mEq)
Number of subjects: 9
Study 31765657 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg testosterone gel
Number of subjects: 111
Study 31765657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 29718751 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical natamycin
Number of subjects: 216
Study 29718751 — intervention group
Group type: COMPARATOR
Intervention: Topical voriconazole
Number of subjects: 216
Study 29206826 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 18
Study 29206826 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 18
Study 29206826 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 18
Study 26304934 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive (PI) strategy
Number of subjects: 1701
Study 26304934 — intervention group
Group type: COMPARATOR
Intervention: Primary percutaneous coronary intervention (PPCI)
Number of subjects: 1701
Study 23794696 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional pre‐adjusted edgewise brackets and elastomeric ligatures
Number of subjects: 45
Study 23794696 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional pre‐adjusted edgewise brackets and Super Slick(®) low friction elastomeric ligatures
Number of subjects: 45
Study 23794696 — intervention group
Group type: EXPERIMENTAL
Intervention: Damon 3MX(®) passive self‐ligating brackets
Number of subjects: 45
Study 21945262 — intervention group
Group type: EXPERIMENTAL
Intervention: HerpV+QS‐21 (saponin adjuvant)
Number of subjects: 35
Study 21945262 — intervention group
Group type: EXPERIMENTAL
Intervention: HerpV
Number of subjects: 35
Study 21945262 — intervention group
Group type: COMPARATOR
Intervention: QS‐21
Number of subjects: 35
Study 21945262 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 35
Study 18297973 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 80
Study 18297973 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 80
Study 16881771 — intervention group
Group type: EXPERIMENTAL
Intervention: Child friendship training (CFT)
Number of subjects: 100
Study 16881771 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control (DTC)
Number of subjects: 100
Study 14567768 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta-estradiol plus intermittent medroxyprogesterone acetate (MPA)
Number of subjects: 118
Study 14567768 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 118
Study 10197829 — intervention group
Group type: EXPERIMENTAL
Intervention: Education-based group intervention
Number of subjects: 312
Study 10197829 — intervention group
Group type: COMPARATOR
Intervention: Peer discussion group intervention
Number of subjects: 312
Study 10197829 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus peer discussion (combination)
Number of subjects: 312
Study 10197829 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 312
Study 7767193 — intervention group
Group type: EXPERIMENTAL
Intervention: Self medication programme
Number of subjects: 88
Study 7767193 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study 2264700 — intervention group
Group type: EXPERIMENTAL
Intervention: Biostim (immunomodulating agent)
Number of subjects: 3008
Study 387230 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with L-PAM
Number of subjects: 0
Study 387230 — intervention group
Group type: COMPARATOR
Intervention: Polychemotherapy
Number of subjects: 0
Study 387230 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with local irradiation
Number of subjects: 0
Study 30630560 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil combined anesthesia
Number of subjects: 154
Study 30630560 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl combined anesthesia
Number of subjects: 154
Study 27639755 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose simulation education with structured debriefing and verbal feedback
Number of subjects: 0
Study 27639755 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 27053091 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublobar resection
Number of subjects: 339
Study 27053091 — intervention group
Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 339
Study 25185456 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus medication (nifedipine 5 mg once daily and beraprost 20 mg three times daily)
Number of subjects: 14
Study 25185456 — intervention group
Group type: COMPARATOR
Intervention: Medication only (nifedipine 5 mg once daily and beraprost 20 mg three times daily)
Number of subjects: 14
Study 25185456 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus medication
Number of subjects: 14
Study 22045030 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulforaphane-rich beverage (SFR)
Number of subjects: 50
Study 22045030 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucoraphanin-rich beverage (GRR)
Number of subjects: 50
Study 22045030 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SFR and GRR
Number of subjects: 50
Study 22045030 — intervention group
Group type: COMPARATOR
Intervention: SFR
Number of subjects: 50
Study 19207781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation guided by barium visualization of the esophageal course using a limit of 15 W
Number of subjects: 175
Study 19207781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation guided by barium visualization using 25 W and 'short burns' (max. 5 sec)
Number of subjects: 175
Study 19207781 — intervention group
Group type: COMPARATOR
Intervention: Ablation without visualization of the esophagus using 25 Watt (W) power limit on the posterior wall
Number of subjects: 175
Study 18008255 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalent HSV‐2 infection
Number of subjects: 0
Study 18008255 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis (BV)
Number of subjects: 0
Study 15831776 — intervention group
Group type: EXPERIMENTAL
Intervention: Adinazolam (10 mg)
Number of subjects: 9
Study 15831776 — intervention group
Group type: EXPERIMENTAL
Intervention: N-desmethyl adinazolam (NDMAD, 10 mg)
Number of subjects: 9
Study 15831776 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (1 mg)
Number of subjects: 9
Study 11978337 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination (Glaxo 1077)
Number of subjects: 663
Study 11978337 — intervention group
Group type: COMPARATOR
Intervention: Placebo or no vaccine
Number of subjects: 663
Study 9704254 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 60
Study 9704254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 60
Study 9704254 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 60
Study 8556082 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcellulose lubricating drops every 2 hours (n = 30)
Number of subjects: 60
Study 8556082 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene film moisture chamber (n = 30)
Number of subjects: 60
Study 28867396 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling
Number of subjects: 0
Study 28867396 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based self-monitoring
Number of subjects: 0
Study 28867396 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined behavioral counseling and technology-based self-monitoring
Number of subjects: 0
Study 28867396 — intervention group
Group type: COMPARATOR
Intervention: Baseline advice
Number of subjects: 0
Study 28482385 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (250 mg/d) orally
Number of subjects: 408
Study 28482385 — intervention group
Group type: COMPARATOR
Intervention: Control group (antibiotic therapy and conventional treatment)
Number of subjects: 408
Study 25594434 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop control (CLC) for 5 consecutive nights (23:00-07:00h)
Number of subjects: 10
Study 24045253 — intervention group
Group type: EXPERIMENTAL
Intervention: 128-slice dual-source CT (DSCT) scanner
Number of subjects: 100
Study 24045253 — intervention group
Group type: COMPARATOR
Intervention: 64-slice MDCT scanner
Number of subjects: 100
Study 21949219 — intervention group
Group type: EXPERIMENTAL
Intervention: FII algorithm (same dose as meal A) applied to meal B (41 g carbohydrate)
Number of subjects: 28
Study 21949219 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate counting applied to meal A (75 g carbohydrate)
Number of subjects: 28
Study 19840302 — intervention group
Group type: EXPERIMENTAL
Intervention: New baby wipe formulation
Number of subjects: 63
Study 19840302 — intervention group
Group type: COMPARATOR
Intervention: Water and washcloth
Number of subjects: 63
Study 18035730 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (1.5-3 g daily)
Number of subjects: 135
Study 18035730 — intervention group
Group type: COMPARATOR
Intervention: Standard antibacterial therapy (betalactams, fluoroquinolones, aminoglycosides, metronidazole)
Number of subjects: 135
Study 18035730 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 135
Study 18035730 — intervention group
Group type: COMPARATOR
Intervention: Standard antibacterial therapy
Number of subjects: 135
Study 15577653 — intervention group
Group type: EXPERIMENTAL
Intervention: N-9 gel
Number of subjects: 180
Study 15577653 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 180
Study 11745232 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest X-ray screening
Number of subjects: 0
Study 11745232 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 0
Study 9046946 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management of carotid atherosclerosis
Number of subjects: 0
Study 9046946 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 0
Study 8233251 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute dosing protocol (incremental dose 1 mU/minute until 5 mU/minute, then 1 or 2 mU/minute)
Number of subjects: 865
Study 8233251 — intervention group
Group type: COMPARATOR
Intervention: 40-minute dosing protocol (incremental dose 1.5 mU/minute until 7 mU/minute, then 1.5 or 3.0 mU/minute)
Number of subjects: 865
Study 8233251 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute dosing protocol
Number of subjects: 865
Study 8233251 — intervention group
Group type: COMPARATOR
Intervention: 40-minute dosing protocol
Number of subjects: 865
Study 3630857 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc picolinate (50 mg elemental zinc per day)
Number of subjects: 15
Study 3630857 — intervention group
Group type: COMPARATOR
Intervention: Zinc gluconate (50 mg elemental zinc per day)
Number of subjects: 15
Study 3630857 — intervention group
Group type: COMPARATOR
Intervention: Zinc citrate (50 mg elemental zinc per day)
Number of subjects: 15
Study 3630857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30770035 — intervention group
Group type: EXPERIMENTAL
Intervention: Victims are female in conflicts
Number of subjects: 370
Study 30770035 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal physical violence
Number of subjects: 370
Study 29611712 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-based intervention
Number of subjects: 375
Study 29802491 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent sucrose intake (Q1 vs Q4)
Number of subjects: 182
Study 29802491 — intervention group
Group type: EXPERIMENTAL
Intervention: Premenarcheal total carbohydrates intake (Q1 vs Q4)
Number of subjects: 182
Study 29802491 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent fiber intake
Number of subjects: 182
Study 29802491 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent fructose intake
Number of subjects: 182
Study 29802491 — intervention group
Group type: EXPERIMENTAL
Intervention: Early adulthood total carbohydrates, glycemic index/load, fiber, and simple sugars intake
Number of subjects: 182
Study 27806024 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cells (DCs) and cytokine-induced killer (CIK) cells infusion (20 mL DCs and CIK cells >1.0×10¹° cells) and 500,000 U interleukin (IL)-2 for 3 days
Number of subjects: 31
Study 27806024 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (30 mg/m²) and 500,000 U IL-2 for 3 days
Number of subjects: 31
Study 23996918 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 88
Study 23996918 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 88
Study 21153642 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonophoresis with betamethasone in conjunction with wrist splint use (group I, n: 18)
Number of subjects: 52
Study 21153642 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis with betamethasone in conjunction with wrist splint use (group II, n: 16)
Number of subjects: 52
Study 21153642 — intervention group
Group type: COMPARATOR
Intervention: Wrist splint use alone (control, group III, n: 18)
Number of subjects: 52
Study 21265282 — intervention group
Group type: EXPERIMENTAL
Intervention: Home spirometry with data transfer via Bluetooth-equipped cell phones
Number of subjects: 56
Study 21265282 — intervention group
Group type: COMPARATOR
Intervention: Home spirometry alone
Number of subjects: 56
Study 18855271 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of trandolapril and verapamil (FDTV) 2/180 mg once a day
Number of subjects: 40
Study 18855271 — intervention group
Group type: COMPARATOR
Intervention: Trandolapril (T) 2 mg once a day
Number of subjects: 40
Study 15889944 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin 100 mg, increased to 3 times daily (maximum 400 mg/day)
Number of subjects: 33
Study 15889944 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 7 mg, increased to 20 mg/day (3 times daily)
Number of subjects: 33
Study 12579547 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered behavioral treatment with written manuals
Number of subjects: 0
Study 12579547 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line pharmacotherapies (nicotine gum, nicotine patch, bupropion)
Number of subjects: 0
Study 12579547 — intervention group
Group type: COMPARATOR
Intervention: Self-administered pharmacotherapies under real-world conditions
Number of subjects: 0
Study 10584635 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile tocolysis (bolus tocolysis) and oral application of magnesium
Number of subjects: 59
Study 10584635 — intervention group
Group type: COMPARATOR
Intervention: Continuous tocolysis and oral application of magnesium
Number of subjects: 59
Study 10584635 — intervention group
Group type: COMPARATOR
Intervention: Continuous tocolysis and parenteral application of magnesium
Number of subjects: 59
Study 8607241 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of 67.2 Gy
Number of subjects: 202
Study 8607241 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of 75.6 Gy
Number of subjects: 202
Study 1931239 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 158
Study 1931239 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 158
Study 6179524 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon for 12 months
Number of subjects: 8
Study 6179524 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 8
Study 31023381 — intervention group
Group type: EXPERIMENTAL
Intervention: Motherfit group therapy (8 sessions of 60 min each, supervised by a registered pelvic physiotherapist)
Number of subjects: 240
Study 31023381 — intervention group
Group type: EXPERIMENTAL
Intervention: Motherfit group therapy
Number of subjects: 240
Study 31023381 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 240
Study 28138164 — intervention group
Group type: COMPARATOR
Intervention: Caudal block with bupivacaine 0.25% (0.50 ml/kg)
Number of subjects: 60
Study 28138164 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous morphine (100 mcg/kg)
Number of subjects: 60
Study 28138164 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block with bupivacaine 0.25% (1 mg/kg)
Number of subjects: 60